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a  b  s  t  r  a  c  t
Background:  Prenatal  exposure  to  bisphenol  A  (BPA)  has  been  shown  to  induce  obesity  in  rodents.  To eval-
uate  if  exposure  also  later in  life  could  induce  obesity  or liver  damage  we investigated  these  hypothesises
in  an  experimental  rat model.
Methods: From  ﬁve  to ﬁfteen  weeks  of age,  female  Fischer  344  rats  were  exposed  to  BPA  via  drinking  water
(0.025,  0.25  or 2.5 mg  BPA/L)  containing  5%  fructose.  Two  control  groups  were  given  either  water  or  5%
fructose  solution.  Individual  weight  of  the  rats  was  determined  once  a week.  At  termination  magnetic
resonance  imaging  was  used  to  assess  adipose  tissue  amount  and distribution,  and  liver  fat  content.  After
sacriﬁce  the  left  perirenal  fat  pad  and  the liver  were  dissected  and  weighed.  Apolipoprotein  A-I in  plasma
was  analyzed  by  western  blot.
Results: No  signiﬁcant  effects  on  body  weight  or the  weight  of the  dissected  fad  pad  were  seen in rats
exposed  to  BPA,  and  MRI showed  no  differences  in total  or  visceral  adipose  tissue  volumes  between
the  groups.  However,  MRI  showed  that  liver  fat content  was  signiﬁcantly  higher in  BPA-exposed  rats
than  in  fructose  controls  (p  =  0.04).  BPA  exposure  also  increased  the  apolipoprotein  A-I levels  in plasma
(p  <  0.0001).
Conclusion: We  found  no  evidence  that  BPA  exposure  affects  fat mass  in  juvenile  fructose-fed  rats.  How-
ever,  the  ﬁnding  that  BPA  in  combination  with  fructose  induced  fat inﬁltration  in the  liver  at  dosages
close  to the  current  tolerable  daily  intake  (TDI)  might  be of  concern  given  the  widespread  use  of  this
compound  in our  environment.Abbreviations: apo A-I, apolipoprotin A-I; BMI, body mass index; BPA, bisphe-
ol  A; HDL, high density lipoproteins; IL-6, interleukin-6; LCAT, lecithin-cholesterol
cyltransferase; LPS, lipopolysaccharide; LSI, liver somatic index; LT, lean tissue;
RI,  magnetic resonance imaging; NOAEL, no adverse effect level; PPAR-, per-
xisome proliferator activated receptor-gamma; SAT, subcutaneous adipose tissue;
RBI, Scavenger Receptor Class B-I; TAT, total adipose tissue; TDI, tolerable daily
ntake; TNF alpha, tumor necrosis factor-alpha; VAT, visceral adipose tissue; VLDL,
ery low density lipoproteins.
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1. Introduction
The prevalence of obesity (BMI > 30) has risen dramatically in
the world over the past two decades. In 2009–2010, 35.5% of adult
men and 35.8% of adult women in the US were obese (Flegal et al.,
2012). Obesity causes negative effects on quality of life while also
predisposing individuals to a number of diseases, including type 2
diabetes and cardiovascular diseases.
Many researchers consider obesity mainly as an unfavorable
balance between a high energy intake and low energy expendi-
ture due to poor diet and inadequate exercise habits. However,
overweight early in life is a risk factor for overweight and obesity
later in life, and paradoxically underweight is another risk fac-
tor due to a “catch up” phenomenon. Obviously there exists some
Open access under CC BY-NC-ND license.sort of programming regarding weight development, at least in the
earliest stages of life. Recent research has suggested that environ-
mental contaminants could play an important role in modulating
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Janesick and Blumberg, 2011). In a study on mice it was  found that
renatal exposure to tributyl tin (TBT) caused obesity later in life
nd the term “obesogens” was coined (Grun and Blumberg, 2006).
his observation supports the hypothesis of fetal programming in
umans as a source of certain disorders, such as obesity and dia-
etes, emerging many years later (Barker et al., 2002). In addition
o fetal programming, exposure to certain chemicals in adulthood
s also important. Adult rats given persistent organic pollutants
POPs) via crude salmon oil become obese (Ruzzin et al., 2010), and
harmaceuticals, such as the antidiabetic drug rosiglitazone (ROSI)
cting on the important receptor peroxisome proliferator-activated
eceptor-gamma (PPAR-) increase body fat when administered to
dult humans (Choi et al., 2010). Moreover, it was recently shown
hat thiazide antihypertensive agents induce visceral obesity when
iven to adult hypertensive patients (Eriksson et al., 2008). Taken
ogether, these data indicates that exposure to chemicals not only
n utero or early childhood could be of importance for the develop-
ent of obesity.
Bisphenol A (BPA) was discovered to be an artiﬁcial estrogen
s early as the 1930s (Dodds, 1936), but the synthesis of another
hemical, diethylstilbestrol (DES), with more potent estrogenic
roperties precluded the use of BPA as a pharmaceutical agent.
oday its main applications are as a hardener in plastic goods and
s a monomer for production of polycarbonate plastics. As such, it
s a high-volume chemical and circulating levels of this compound
ere measureable in about 98% of all subjects in a study of Swedish
lderly persons (Olsen et al., 2012) conﬁrming the National Health
nd Nutrition Examination Survey (NHANES) 2007–2008 where
he urinary concentrations were measurable in 94% of the subjects
<LOD 6.1%) (LaKind et al., 2012).
BPA is almost completely absorbed in the gastrointestinal tract
n humans and is highly conjugated to form the major metabo-
ite bisphenol A glucuronide by ﬁrst pass metabolism in the liver
Pottenger et al., 2000). The glucuronide, which is not estrogenically
ctive, is then cleared from blood by elimination with urine. In rats
he main route of elimination of conjugated BPA is by biliary and
ecal elimination which enables enterohepatic recirculation (Völkel
t al., 2002). These mechanisms indicate that the metabolism of
PA is faster and the conjugation more efﬁcient in humans, where
nterohepatic recirculation is negligible, than in rats. However,
train differences has been reported, and in female Fischer 344 (F
44) rats the excretion via urine was 42%, and twice as high as in
D rats (21%) (Snyder et al., 2000). The efﬁcient conjugation and
elatively low BPA-exposure are the main reasons why  BPA is con-
idered to be safe to humans despite a notable amount of animal
tudies demonstrating effects on various outcomes and in various
oses. One mechanism to further evaluate is the action of the -
lucoronidase enzyme present within many tissues, notably e.g.
he placenta of animals and humans. -Glucoronidase deconju-
ates BPA to its active form which may  lead to fetal exposure in
he uterus (Ginsberg and Rice, 2009). There has been a focus on
PA as an endocrine disruptor because of its estrogenicity, while
here also might be other mechanisms that explain the effects of
PA seen in various studies.
Prenatal exposure to BPA in rodents has previously been shown
o induce obesity (Miyawaki et al., 2007; Somm et al., 2009; Wei
t al., 2011), and the effect of exposure to BPA later in life has
ecently been studied by e.g. Marmugi et al. (2012).  But there is an
nconsistency regarding BPA exposure and weight gain since other
tudies show no signiﬁcant effects despite exposure over genera-
ions in the environmentally relevant doses (Ema  et al., 2001; Tyl
t al., 2008, 2002).In order to study effects of BPA in doses in the range of tolerable
aily intake (TDI) we have used three exposure levels, the medium
ose being close to TDI as established by the U.S. Environmental
rotection Agency (EPA) and the European Food Safety Authority03 (2013) 125– 132
(EFSA) at 50 g/kg and day. The low dose was 10 times lower and
the high dose 10 times higher than the medium dose.
The primary aim of this study was to test the hypothesis that
exposure to BPA in combination with carbohydrates after the sen-
sitive prenatal and perinatal periods also could affect fat mass or
liver fat content. Since exposure to BPA only, later in life (Marmugi
et al., 2012) and perinatal exposure to BPA in combination with high
fat diet later in life (Wei  et al., 2011) have been reported, this study
will focus on exposure to BPA in combination with a diet supple-
mented with carbohydrates. As fructose is a widely used sweetener
in processed food and has been suggested to contribute to unfavor-
able metabolic alterations (Bocarsly et al., 2010; Bremer et al., 2012)
juvenile rats were exposed to BPA in combination with a 5% fructose
solution, which is about the same fructose concentration as in com-
mon  soft drinks (9–13% sucrose). Effects on adipose tissue volume
and liver fat content in the BPA-exposed groups were evaluated by
magnetic resonance imaging (MRI) and compared with a control
group also given fructose solution. As a secondary aim, we inves-
tigated whether obesity parameters and the liver were affected by
fructose feeding alone, using water-fed rats as a control group.
2. Material and methods
2.1. Chemicals
Bisphenol A (BPA), (80-05-7, (CH3)2C(C6H4OH)2, ≥99% purity), fructose
(C6H12O6, ≥99% purity), Griess modiﬁed reagent, ZnSO4, and VCl3 were purchased
from Sigma–Aldrich, St. Louis, MO.  NaNO3 was purchased from Merck chemicals,
Darmstadt, Germany.
2.2. Animals
The animal study was  approved by the Uppsala Animal Ethical Committee
and followed the guidelines laid down by the Swedish Legislation on Animal
Experimentation (Animal Welfare Act SFS1998:56) and European Union Legislation
(Convention ETS123 and Directive 86/609/EEC).
Sixty female F 344 rats at 3 weeks of age were purchased from Charles River
International, Salzfeld, Germany, and housed 3 rats/cage at Uppsala University Hos-
pital  animal facility in a temperature-controlled and humidity-controlled room
with a 12-h light/dark cycle. To minimize background BPA exposure Polysulfone
IV  cages (Eurostandard IV) and glass water bottles were used. The rats were fed a
standard pellet RM1  diet (ad lib.) from NOVA-SCB, Sollentuna, Sweden. RM1  is a
natural ingredient diet with a low level of phytoestrogens (100–200 g/g) (Jensen
and Ritskes-Hoitinga, 2007; Odum et al., 2001). During the two-week acclimatiza-
tion period preceding the ten-week intervention all animals were given water to
drink and during the intervention water or 5% fructose solution (see Section 2.3). At
5  weeks of age the rats were assigned to ﬁve groups (12 rats/group); water control
(W), fructose control (F), low dose BPA (0.025 mg/L), medium dose BPA (0.25 mg/L)
or  high dose BPA (2.5 mg/L). To avoid unnecessary stress no cage-mates were sep-
arated, but the cages were allocated to the different groups to achieve equality in
weights in all groups. Food and liquid consumption in each cage and individual
weight of the rats were determined once a week.
Before MRI  exam, the rats were anesthetized with Ketalar 90 mg/kg bw (Pﬁzer,
New York, NY) and Rompun 10 mg/kg bw (Bayer, Leverkusen, Germany). Immedi-
ately after the scanning they were killed by exsanguinations from the abdominal
aorta while still under anesthesia.
2.3. Exposure
To prepare BPA exposure solutions (0.025, 0.25 and 2.5 mg/L), three stock solu-
tions of BPA in 1% ethanol (2.5 mg/L, 25 mg/L and 250 mg/L) were diluted 1:100 in 5%
fructose solution. The low dose was  chosen to be well below the recommended TDI,
the medium dose corresponding to TDI (50 g/kg and day), while the highest dose
was ten times this level. The BPA was analyzed by liquid chromatography–tandem
mass spectrometry by the Division of Occupational and Environmental Medicine in
Lund, Sweden. The division is a European reference laboratory in the DEMOCOPHES
EU  project (www.eu-hbm.info/democophes) for analysis of BPA. The BPA concen-
trations in analyzed samples of the solutions were: water control – 0.00020 mg/L;
fructose control – 0.00011 mg/L; BPA 0.025 mg/L – 0.029 mg/L; BPA 0.25 mg/L –
0.25 mg/L and BPA 2.5 mg/L – 2.7 mg/L.
The exposure solutions were given ad lib. for ten weeks and exposure levels
are  presented in Table 1. The water control rats and the fructose control rats had
free access to water containing 1% ethanol, and 5% fructose solution containing 1%
ethanol, respectively. Groups given fructose solution drank more than the water
control rats, and also raised their liquid consumption during the experiment, but ate
less. The control group given water had an almost constant food and liquid intake.
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Table  1
Exposure of bisphenol A, liquid and food consumption (RM1 ad lib.) and energy intake during the ten-week study of juvenile female Fischer 344 rats given either water or a
5%  fructose solution or bisphenol A (BPA) – 0.025, 0.25 or 2.5 mg/L – dissolved in a 5% fructose solution. Food and liquid consumption are measured per cage (4 cages/group)
and  all values are given as the calculated mean/rat. N = 12/group, w = week.
Control:water Control:5%
fructose solution
BPA 0.025 mg/L + 5%
fructose solution
BPA 0.25 mg/L + 5%
fructose solution
BPA 2.5 mg/L + 5%
fructose solution
BPA exposure, mean w 1–10 (g/kg/day) 0 0 5.1 54.3 487.3
BPA  exposure highest (g/kg/day) 0 0 5.6 (w 2) 61.6 (w 3) 595.3 (w 2)
BPA  exposure lowest (g/kg/day) 0 0 4.6 (w 9) 46.3 (w 6) 400.3 (w 9)
Liquid,  mean w 1–10 (g/rat and day)d 11.5 28.3 28.1 30.1 24.7
Liquid w 1 (g/rat/day) 11.6 20.8 20.4 21.8 19.8
Liquid w 10 (g/rat/day) 10.8 32.0 33.0 36.8 29.4
Food,  mean w 1–10 (g/rat and day)d 10.2 8.7 8.5 8.3 8.7
Food  w 1 (g/rat/day) 10.8 10.1 10.0 9.6 9.3


















































dFructose energy mean w 1–10 (kcal/rat/day) 0 5.7 
Food  energy mean w 1–10 (kcal/rat/day) 28.9 24.6 
Energy tot mean w 1–10 (kcal/rat/day) 28.9 30.3 
ifference in mean caloric intake was less than 5% between the groups with highest
nd lowest caloric intake.
.4. Magnetic resonance imaging and post processing
The MR imaging was performed on a 1.5 T clinical MR  system (Achieva; Philips
ealthcare, Best, Netherlands) using a quadrature knee coil. The rats lay in prone
osition. MR compatible pads were used to position the animal in the coil cen-
er. Two bottles of warm tap water were positioned next to the rats to help them
aintain their body temperature.
Two different MR  protocols were used. A whole-body single echo water–fat
maging protocol was  used to analyze adipose tissue distribution. A 32-echo
ater–fat imaging protocol covering most of the liver was used to analyze liver
at  content and the relaxation parameter R2* using model-based ﬁtting to time
omain data. This model-based determination of fat content and R2* is similar to
uantiﬁcation of resonance peak heights and widths, respectively, from the cor-
esponding MR spectrum. The image data and the analysis used are illustrated in
ig.  2.
The whole-body imaging was performed using a volume of interest
100 mm × 100 mm × 150 mm,  sagittal × coronal × axial) positioned to cover the
olume from neck to tail, see Fig. 1a. A spoiled 3D single gradient-echo pro-
ocol with imaging parameters repetition time 8 ms, echo time 3.2 ms, and ﬂip
ngle 12◦ was used. The acquired voxel size was  0.5 mm × 0.5 mm × 1.0 mm.  The
econstructed voxel size was 0.45 mm × 0.45 mm × 1.0 mm.  Fold-over direction was
nterior–posterior. Total imaging time, using one signal average was  4 min  17 s.
ater fat shift was  0.486 pixels. No parallel imaging was used.
Water and fat images were reconstructed from the complex single echo image
ata using a previously presented model-based method (Berglund et al., 2010). The
ossibility to separate water and fat signal from a single echo acquisition can be
ather intuitively realized. The echo time used in the current protocol gives an
pproximate phase shift of 270◦ between water and fat. Hence, after correction for
0 inhomogeneity, the water and fat signal vectors are aligned along the positive
eal axis and negative imaginary axis, respectively. In brief, the algorithm deter-
ined the water and fat content in each voxel using three assumptions. First, the
ajority of voxels were assumed to have one of two  different water:fat signal ratios.
he assumed ratios were 100:0, for muscles and organs, and 0:100, for adipose tis-
ue.  Second, the static magnetic ﬁeld distribution was assumed to be smooth. Third,
oxels with an equal amount of fat and water were located on interfaces between
ater-dominant regions and adipose tissue. The ﬁrst assumption left two  possible
lternatives for the static magnetic ﬁeld in each voxel. Using the second assumption,
he right alternative could be selected using optimization. In this study a multi-scale
elief propagation approach was used (Felzenszwalb and Huttenlocher, 2006). To
llow a continuous spectrum of water:fat ratios, the phase map was  ﬁltered using an
veraging ﬁlter. The determination of the static magnetic ﬁeld distribution allowed
irect calculation of the water and fat components. Method feasibility has previ-
usly been demonstrated in whole-body scans of a human subject at both 1.5 T and
.0  T (Berglund et al., 2010).
Volumes of total, visceral, subcutaneous adipose tissue, and lean tissue (TAT,
AT, SAT, and LT, respectively) were quantiﬁed using a semi-automated approach.
at  fraction images, deﬁned by fat/(fat + water), were calculated and adipose tissue
nd lean tissue were separated by thresholding at 50% fat fraction.
To reduce the effect of fat fractions originating from background and low sig-
al  regions in the analysis, the tissue of the rats was  separated from background
y clustering. The water and fat images were clustered into three classes (adipose
issue, lean tissue, and background) using a version of Fuzzy C-means that incorpo-
ates spatial continuity (Liew et al., 2005). Fat fractions originating from noise in low
ignal regions were suppressed by multiplying by the background cluster inverse.
The  VAT volume was  segmented from the fat fraction image using a previously
escribed semi-automated method (Malmberg et al., 2009). The operator manually5.6 6.0 4.9
24.1 23.5 24.6
29.7 29.5 29.5
placed foreground seeds in the VAT depot and background seeds in SAT, mus-
cles, organs, and in the background. The algorithm then determined the boundary
between VAT and other tissues. The operator interactively added/removed seeds in
a  three-plane view until the segmentation was visually determined to be accurate.
Two  operators segmented the VAT depot in all animals. The mean VAT volume was
used  (mean CV was 1.40%). The subcutaneous adipose tissue volume was  calculated
as  the difference between the TAT and VAT volumes.
The 32-echo water–fat liver imaging was performed using a 3D spoiled
gradient echo acquisition with the following scan parameters: Field of view,
95 mm × 95 mm × 15.6 mm (sagittal × coronal × axial), acquired and reconstructed
voxel size, 1.19 mm isotropic, repetition time, 55 ms, ﬁrst echo time, 1.628 ms,  inter
echo spacing, 1.274 ms, ﬂip angle, 35◦ . Imaging time 1 min  46 s. The water–fat image
reconstruction was performed using a previously described method that employs
a  whole-image optimization approach (Berglund and Kullberg, 2012). A multi-peak
triglyceride spectrum model derived from liver MR spectroscopy (Hamilton et al.,
2010)  and a common R2* for all peaks were used in the modeling. The R2* parameter
can be thought of as the peak width in frequency domain and can be used to detect
liver  iron deposition (positive correlation). In the present study, the R2* parameter
was used as an additional biomarker of liver status. The liver fat content and R2*
from the entire liver was  analyzed by manual identiﬁcation of the volume of inter-
est and by ﬁtting of a Gaussian function to the liver fat fraction and R2* histograms
(see Fig. 1f and g). The center of the Gaussian function was used to sample robust
estimates of liver fat content and R2*.
2.5. Tissue sampling
At termination blood was collected from the abdominal aorta in EDTA-treated
tubes (Greiner bio-one, Frickenhausen, Germany) and centrifuged for 10 min to
prepare plasma. Aliquotes were stored at −70 ◦C pending biochemical analyses of
the  following circulating markers: triglycerides, cholesterol, and apolipoprotein A-
I  (apo A-I). The liver and the left perirenal fat pad (see Fig. 2) were dissected and
weighed. The liver weight was used to calculate the liver somatic index (LSI, liver
weight × 100/body weight).
2.6. Biochemistry
The analysis of cholesterol and triglycerides was a standard laboratory technique
and was performed on an Architect C 8000 analyzer (Abbott Laboratories, Abbott
Park, IL, USA) and reported using SI units. Analysis of protein apo A-I: Prior to western
blot 1 l of plasma from rats of all groups (W;  n = 12, F; n = 12, BPA 0.025 mg/L; n = 11,
BPA 0.25 mg/L; n = 8 and BPA 2.5 mg/L; n = 9) were separated on SDS-polyacrylamide
gradient gels (T = 5–20%, C = 1.5%) with stacking gels (T = 5%, C = 1.5%) for 1 h (180 V,
60 mA)  in electrode buffer (0.15% (w/v) Tris, 0.72% (w/v) glycine, 0.05% (w/v) SDS)
using a Mini Protean II electrophoresis cell (Bio Rad). Samples were diluted in sample
cocktail (4% (w/v) SDS, 200 mM DTT, 20% (w/v) sucrose) and boiled for 3 min. Plasma
proteins separated by SDS PAGE were transferred to a PVDF membrane. After block-
ing  1 h (5% milk in TBS) and incubation over night with primary antibodies 1:1000
(2% milk in TTBS) against apo A-I (rabbit anti rat apoA-I, polyclonal, Ab 20453, Abcam,
UK), the membrane was incubated for 1 h with goat anti-rabbit HRP-conjugated
secondary antibodies 1:40 000 (2% milk in TTBS). Proteins were visualized using
an ECL plus western blotting detection system. Gel images were evaluated using
Image Lab 3.0.1 (Bio Rad, Hercules, CA) and apo A-I levels were determined as
intensity/mm2.2.7. Statistical analysis
Differences between the fructose control group and the three BPA plus fructose
exposed groups were evaluated by factorial ANOVA. When the three BPA groups
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Fig. 1. Illustration of the MR  image data and post processing. In (a) one coronal slice from a whole body fat image is shown with a red overlay of the segmented VAT depot.
In  (b–e) one axial slice from the liver scan is shown, where (b) shows the reconstructed w
The  manually segmented region of the liver is illustrated by the yellow delineation. Ima
signal  fraction and R2* data, respectively, from the delineated liver volume.
Fig. 2. Illustration of the location and shape of the left fat pad (see arrow).ater image, (c) the fat image, (d) the signal fat fraction image, and (e) the R2* image.
ges (f) and (g) show the distributions, and the ﬁtted Gaussian functions, of the fat
were analyzed vs the fructose control group one by one, a Bonferroni adjustment
for  3 tests was  used and p < 0.0167 considered signiﬁcant (p = 0.05/3 = 0.0167).
In  the secondary analysis, when the water control group was compared with
the fructose control group p < 0.05 was considered as signiﬁcant.
StatView (SAS Inc, USA) was used for calculations.
3. Results
3.1. Primary aim
No differences between the four fructose-fed groups were seen
regarding the initial body weight recorded prior to the intervention
(p = 0.83, Table 2). Neither did the weight at the time of termination
of the experiment (p = 0.84), nor the weight gain during the inter-
vention (p = 0.68), differ between the four groups. No differences
were found between the four groups regarding the weight of the
fat pad (p = 0.32), and MRI  showed no differences in total or vis-
ceral adipose tissue volumes between the four groups (see Table 2
for details).
However, MRI  revealed a greater fat inﬁltration in the liver
of BPA-exposed rats than in the fructose-fed control rats. In the
medium-dose and the high-dose group of BPA exposed rats the liver
fat content was  higher when compared with the fructose control
group (p = 0.011, medium dose; p = 0.012, high dose). The lowest
dose of BPA did not signiﬁcantly inﬂuence liver fat content (Fig. 3).
Also the MRI  liver R2* analysis showed an effect on the liver by BPA,
being signiﬁcant in all three groups when compared one by one
to the fructose control group (low-dose; p = 0.0008, middle-dose;
p < 0.0001, high-dose; p = 0.0161, Table 2).
A similar picture emerged, although not as pronounced as for
the R2* signal, when the liver somatic index (LSI) was investigated.
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Table  2
Details of initial body weight and results of weight gain, adipose and lean tissue volumes, liver weight and circulating markers in juvenile female Fischer 344 rats in a study
with  two control groups given either water or a 5% fructose solution and three exposed groups given bisphenol A (BPA) – 0.025, 0.25 or 2.5 mg/L – dissolved in 5% fructose
solution for ten weeks. Numbers of observations are 12 if not otherwise stated. The p-values represent the ANOVA p-value for a difference between the four fructose-fed
groups (control group with only fructose and the three groups given fructose plus BPA). All values are given as mean ± SD.
Control: water Control: 5% fructose
solution
BPA
0.025 mg/L + 5%
fructose solution
BPA
0.25 mg/L + 5%
fructose solution




Initial body weight (g) 92.6 ± 10.5 87.8 ± 13.6 84.7 ± 11.1 88.7 ± 10.3 88.3 ± 11.7 0.83
Weight gain, week 1–10 (g) 80.1 ± 9.0 86.2 ± 14.4 88.3 ± 7.7 82.6 ± 8.9 86.4 ± 13.9 0.68
Body  weight at sacriﬁce 172.3a ± 5.4 171.7 ± 7.2 173.7 ± 9.9 172.9 ± 11.8 175.1 ± 8.2 0.84
Estimated body weight, MRI  (g) 148.4 ± 4.7 149.1 ± 5.9 151.5 ± 9.2 149.6 ± 9.5 153.1 ± 8.0 0.63
Total  adipose tissue (cm3) 28.2 ± 3.4 29.8 ± 5.7 29.6 ± 4.9 28.9 ± 5.2 31.7 ± 5.0 0.60
Visceral adipose tissue (cm3) 13.9 ± 1.5 14.3 ± 3.0 13.9 ± 2.4 13.8 ± 2.6 15.3 ± 2.8 0.57
Subcutaneous adipose tissue (cm3) 14.4 ± 2.0 15.4 ± 2.8 15.6 ± 2.6 15.1 ± 2.9 16.4 ± 2.3 0.65
Lean  Tissue (cm3) 95.5 ± 2.9 95.2 ± 4.3 96.6 ± 5.0 95.4 ± 6.0 96.1 ± 6.5 0.92
Liver  fat (%) 5.5 ± 1.0 5.6a ± 0.86 6.4 ± 1.2 7.0 ± 1.7* 6.9 ± 0.73* 0.037
Liver  R2* (1/s) 45.7 ± 3.3 46.5 ± 3.6 51.6 ± 3.8*** 53.6 ± 4.1*** 50.1 ± 2.2* <0.001
Fat  pad (g) 0.74 ± 0.15 0.86 ± 0.21 0.77 ± 0.14 0.76 ± 0.14 0.88 ± 0.25 0.32
Fat  pad/bodyweight ratio (%) 0.43 ± 0.08 0.50 ± 0.11 0.44 ± 0.07 0.44 ± 0.08 0.50 ± 0.13 0.28
Liver  (g) 4.8 ± 0.29 5.1 ± 0.20 5.6 ± 0.86 5.6 ± 0.68 5.4 ± 0.43 0.19
Liver  somatic index (LSI) 2.8 ± 0.16 3.0 ± 0.10** 3.2 ± 0.32* 3.2 ± 0.34* 3.1 ± 0.17 0.08
Cholesterol (mmol/L) 3.0 ± 0.17 3.1 ± 0.23 3.2 ± 0.16 3.1a ± 0.20 3.3 ± 0.20 0.24
Triglycerides (mmol/L) 0.88 ± 0.22 1.3 ± 0.36* 1.7 ± 0.62 1.7a ± 0.79 1.6 ± 0.83 0.48
Apo  A-I (intensity/mm2) 5648 ± 1249 5967 ± 1714 7622a ± 2468 11 271b ± 3049*** 10 524c ± 2023*** <0.001
Glucose week 9 (mmol/L) 4.6 ± 0.79 4.7 ± 0.70 4.5 ± 0.45 4.4 ± 0.36 4.5 ± 0.53 0.49
ASAT  0.95 ± 0.052 0.96 ± 0.22 1.24 ± 1.3 1.32a ± 1.29 1.02 ± 0.22 0.75
ALAT 0.82 ±  0.097 0.73 ± 0.087 0.82 ± 0.41 0.80a ± 0.19 0.76 ± 0.16 0.79
a n = 11.
b n = 8.
c n = 9.
* p < 0.05.
** p < 0.01.












2*** p < 0.001.
hen given after values in the fructose control group this indicates a difference v
ndicates a difference vs the fructose control group.
SI was increased in the low-dose (p = 0.043, not signiﬁcant follow-
ng Bonferroni adjustment) and middle-dose group (p = 0.018, not
igniﬁcant following Bonferroni adjustment), but not signiﬁcantly
o in the high-dose group when compared with the fructose-fed
ontrol rats (Table 2).Both the medium-dose and high-dose of BPA groups showed sig-
iﬁcantly higher levels of plasma apo A-I, when compared with the
ructose control group (p < 0.0001, medium dose; p < 0.0001 high
ig. 3. Liver fat content (%) (mean ± SEM, water; n = 12, fructose; n = 11, BPA
.025 mg/L; n = 12, BPA 0.25 mg/L; n = 12 and BPA 2.5 mg/L; n = 12) in juvenile female
ischer 344 rats given water, 5% fructose solution or bisphenol A (0.025, 0.25 or
.5  mg/L) dissolved in 5% fructose solution for ten weeks.water control group. When given after values in any of the three BPA groups this
dose). The lowest dose of BPA did not cause any signiﬁcant differ-
ence in apo A-I (Fig. 4). Plasma cholesterol and plasma triglycerides
were not signiﬁcantly altered by the BPA exposure. Neither was
blood glucose at week 9, or ASAT and ALAT altered by BPA exposure.
3.2. Secondary aimOf all variables studied (see Table 2), only plasma triglycerides
and LSI were signiﬁcantly increased by fructose feeding alone
when compared to the water-fed control p = 0.0011 and p = 0.0031,
respectively.
Fig. 4. Apolipoprotein A-I (INT/mm2) (mean ± SEM, water; n = 12, fructose; n = 12,
BPA 0.025 mg/L; n = 11, BPA 0.25 mg/L; n = 8 and BPA 2.5 mg/L; n = 9) in juvenile
female Fischer 344 rats given water, 5% fructose solution or bisphenol A (0.025,
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. Discussion
.1. BPA, fructose and lipid metabolism
The present study disclosed no evidence that BPA exposure in
uvenile female fructose-fed F 344 rats would increase fat mass,
espite the use of both weights and MR  imaging based detailed
uantiﬁcation of different adipose tissue compartments. However,
he observed increase in liver fat inﬁltration, detected by MRI  in
arallel with increase in LSI, although in the latter case not sig-
iﬁcant following strict Bonferroni correction for multiple testing,
ven at dosages close to TDI, is a ﬁnding that warrants further
nvestigations.
Interestingly, an increase in liver fat inﬁltration appeared at the
iddle dose, but was not further increased at the highest BPA dose.
his ﬁnding conﬁrms a previous in vivo study on mice by Marmugi
t al., using the same dose range of BPA as in the present study,
ut without fructose. The Marmugi study showed an impact on
he hepatic transcriptome, particularly on genes involved in lipid
ynthesis and that various transcription factors followed a non
onotonic dose–response curve (Marmugi et al., 2012). In addi-
ion, also in line with the Marmugi study, the most signiﬁcant
ffects were observed within one magnitude around the current
DI. However, Marmugi et al. used mice and did not combine BPA
ith fructose, so our study is not entirely comparable with theirs.
Low-dose effects of BPA are currently highlighted and under dis-
ussion worldwide (Rhomberg and Goodman, 2012; Richter et al.,
007; Ryan et al., 2010; Vandenberg et al., 2012) and therefore three
osages were used, of which the medium dose corresponded to
he deﬁned human TDI, as established by the U.S. Environmental
rotection Agency (EPA) and the European Food Safety Authority
EFSA) at 50 g/kg and day. TDI is equal to NOAEL (5000 g/kg and
ay, this is the highest dose which did not induce any adverse
ffect in animal testing), divided by a factor of 100 to compen-
ate for possible species differences in sensitivity. The current TDI
s assumed to be considerably higher than the calculated human
xposure. However, in the present study and others, effects are
een in rats and mice at doses close to the current TDI and even
t lower doses (Richter et al., 2007). Low dose effects of environ-
ental contaminants have previously been suggested based on
pidemiological studies, as well as in experimental settings using
PA (Lee et al., 2011; Marmugi et al., 2012; Rubin et al., 2001;
oriano et al., 2012). Also non monotonic relationships are sug-
ested in e.g. a study by Wei  et al. where pregnant Wistar rats
ere exposed to BPA (50, 250 or 1250 g/kg bw and day) and
heir offspring given normal or high fat diet after weaning. Only
he lowest dose (50 g/kg and day) resulted in such effects as
ncreased body weight, elevated serum insulin and impaired glu-
ose tolerance in adult offspring. In the rats fed a high fat diet
he effects were exacerbated and included metabolic syndrome
obesity, dyslipidemia, hyperleptindemia, hyperglycemia, hyper-
nsulinemia and glucose intolerance). Rats perinatally exposed to
he higher doses did not show any of the adverse effects regard-
ess of diet (Wei  et al., 2011). A similar study has been performed
ith CD-1 mice by Ryan et al. but with a different conclusion. In this
xperiment the mice exposed to BPA (approximately 0.25 g/kg bw
nd day via the diet) during gestation and lactation had heavier
nd longer pups at weaning than pups from the control groups,
ut the differences did not persist until adulthood, regardless of
 high fat or low fat diet given from 9 weeks of age. As in our
tudy MRI  was used to determine body composition and no increase
n body fat was seen in the BPA exposed rats (Ryan et al., 2010).
owever, these studies are not fully comparable due to differences
egarding doses and species and the time point when the modi-
ed diet was introduced. Further Ryan et al. housed their mice in
ages made of polycarbonate and used water bottles also made of03 (2013) 125– 132
polycarbonate, which might have been sources of BPA contamina-
tion in the control groups masking subtle effects, though it was
otherwise a very sound study.
The above mentioned studies were carried out with rodents
which are said to be poor models for BPA in humans due to dif-
ferent toxicokinetics. According to a study by Tominaga et al.
using nonhuman primates; chimpanzees (Pantroglodytes verus)
and cynomolgus monkeys (Macaca fascicularis), there are differ-
ences also among different primate species. In rodents the BPA
T½ is longer, primarily explained by enterohepatic recirculation
in rodents but not in primates. The conjugation rate in the liver
is faster in rodents than in primates, primarily explained by a
higher hepatic blood ﬂow-rate in rodents (Tominaga et al., 2006).
However, there seem to be no differences in the metabolites
formed e.g. it is a question of rate and time and not in the fate
of BPA. The calculated mean exposure in humans is well below
the TDI, but there are still uncertainties about the exact sources
of exposure. Further, based on the WHO  report: “Joint FAO/WHO
Expert Meeting to Review Toxicological and Health Aspects of
Bisphenol A Summary Report” (http://www.who.int/foodsafety/
chem/chemicals/BPA Summary2010.pdf),  the most sensitive indi-
viduals –newborn babies – are also the ones with highest exposure.
According to this report the highest estimated exposure occurs in
infants 0–6 months of age who are fed with liquid formula out of
PC bottles: 2.4 g/kg bw per day (mean) and 4.5 g/kg bw per day
(95th percentile), which is very close to the lowest dose used in the
present study. In children, teenagers and adults the mean exposure
was <0.01–0.40 g/kg bw per day.
Prenatal exposure to BPA has been shown to increase expression
of lipogenic genes and adipocyte size in rodents (Marmugi et al.,
2012; Somm et al., 2009). Studies on isolated cells have shown
BPA to induce production of proinﬂammatory cytokines, such as
IL-6 and TNF-alpha (Yamashita et al., 2005), and to induce expres-
sion of adipogenic transcription factors (Phrakonkham et al., 2008),
including PPAR-gamma activation (Kwintkiewicz et al., 2010). How
these in vitro ﬁndings relate to the present ﬁnding of an increase
in liver fat inﬁltration in combined exposure to fructose and BPA is
not understood.
The above-mentioned study by Marmugi et al. further suggests
that exposure to low BPA doses may  inﬂuence de novo fatty acid
synthesis and thereby contributing to hepatic steatosis in mice
(Marmugi et al., 2012). Interestingly, fructose has also been pointed
out as a possible contributor to similar effects on the liver by its
interaction with the Glut5 receptor (Lustig, 2010). In line with
Lustig, it has been suggested by others, summarized in a review
by Yilmaz (2012) that high fructose diet (60–70% of total energy
intake) may  contribute to non-alcohol fatty liver disease, metabolic
syndrome, formation of advanced glycated end products as well as
direct dysmetabolic effects on liver enzymes.
In the present study, it can be concluded that 5% fructose
alone or in combination with BPA results in unfavorable metabolic
alterations. There are three possible sources of increases in liver
fat; de novo lipid synthesis, decreased degradation or increased
transport of cholesteryl esters to the liver. According to our data
the most likely mechanisms behind the lipid accumulation in the
liver are a combination of de novo lipid synthesis and increased
reversed transport (also Section 4.2). The individual contribution
from fructose and BPA can only be postulated, but according to the
liver fat accumulation in the fructose group and further increase
accompanied by the increase of plasma apo A-I (Fig. 4) after BPA
exposure, we suggest that fructose is the main contributor to
the de novo lipid synthesis while BPA is the main contributor
to the increased reverse transport. The decrease in plasma apo
A-I and thereby LSI at the highest BPA dose may  be a negative
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In addition, in the three-generation reproductive toxicity study
f dietary bisphenol A in CD Sprague-Dawley rats, by Tyl et al.
2002) rats of both sexes were exposed to BPA in six different
oncentrations between 0 and 7500 ppm for three generations
nd analyzed for many different outcomes. The study is consis-
ent with ours regarding the weight gain of the rats, which was
ot signiﬁcantly different in the doses used in either study. The
nly consistent effects of BPA in the three-generation study are
oxic effects in the highest doses seen as e.g. decreased body
eights. The results of the histopathology are somewhat hard
o interpret because of aberrances in the control groups. One
f the variables that did show signiﬁcant effects in the second
eneration was the liver weights in female rats exposed to BPA
n about the same actual dose range (0.7–30 g/kg/day) as ours
5, 54, 487 g/kg/day). One can argue that the effect was  not
onsistent between generations and sexes, but also notice the reap-
earance of similar results in different studies. We  assume that
here are differences in vulnerability for BPA between sexes, dif-
erent species and strains of rats, periods in life and also between
ndividuals of the same species, e.g. humans, thus explaining the
esults.
.2. BPA, apo A-I and immunity
Plasma Apo A-I, the dominating protein in high-density
ipoproteins (HDL), is by its interaction with lecithin-cholesterol
cyltransferase (LCAT) a crucial component in the cholesterol
ransport to the liver. In addition, apo A-I has anti-inﬂammatory
roperties via interactions with the immune system (Henning et al.,
011; Smoak et al., 2010; Yu et al., 2010) and in a recent study
arlsson et al. have also shown binding between apo A-I and
ano-sized metal oxides (Karlsson et al., 2012). The mechanisms
ehind elevated plasma apo A-I levels in response to BPA exposure
as to be further investigated and there are at least four differ-
nt possibilities; (i) induced apo A-I gene expression by BPA, as
as been reported regarding Aspirin (Jaichander et al., 2008), (ii)
ncreased apo A-I expression in response to (pro)-inﬂammatory
ffects caused by BPA, (iii) that BPA, due to its structural simi-
arities to cholesterol is in fact recognized as free cholesterol and
iv) that BPA causes oestrogenic effects on apo A-I gene expres-
ion (Duvillard et al., 2009). As shown in Fig. 4, apo A-I is also
lightly increased in the fructose group. This is in line with a
tudy by Koo et al., where rats fed with high doses of fruc-
ose (63%) showed altered lipid metabolism and increased apo
-I levels (Koo et al., 2008). The increased expression of apo A-
 may  result in BPA elimination from the plasma together with
holesteryl esters via the Scavenger Receptor Class B-I (SR-BI) in
he liver. The interaction between apo A-I and SR-BI may  thereby
esult in non-endocytotic hepatocytic uptake of hydrophobic com-
ounds, such as cholesteryl esters and also possibly BPA. This
ould explain the inverted plasma cholesterol levels, albeit not
igniﬁcant, compared to apo A-I levels and also the increased
at inﬁltration in livers of BPA-exposed rats (Table 2 and Fig. 3).
nterestingly, and in line with our ﬁndings, cholesteryl ester accu-
ulation in the liver of mice exposed to BPA has previously
een observed by Marmugi et al. (2012).  The fate of BPA in the
iver is not entirely known but elimination via bile or readmis-
ion into the circulation via very-low-density lipoproteins (VLDL)
re options that need to be further investigated. Less is known
bout impacts of BPA on the liver and there are only a few
ther animal studies carried out, showing e.g. formation of DNA
dducts and impaired mitochondrial functioning (Izzotti et al.,
009; Moon et al., 2012). However, due to disparities in e.g. doses
nd exposure route these studies are not comparable with our
tudy.03 (2013) 125– 132 131
4.3. Strengths and limitations
The strength of our study is that both fat pad weights and liver
weights and extensive MR  imaging-based techniques were used to
quantify different fat depots, and the liver fat content. The 32-echo
MR liver scan had relatively low spatial resolution. This resolution
was high enough, however, for delineation of the liver tissue and the
collection of 32 echoes allowed robust estimation of liver fat frac-
tion and R2* values. We  believe that the delineation of the entire
liver volume imaged in combination with the analysis of the data
distributions gave robust estimates of the liver tissue properties.
It is possible that the higher R2* values measured in the exposed
groups are due to iron inﬁltration of the liver tissue. Other pos-
sible causes might be due to changes in tissue structure. Another
strength of the study is that LSI, liver fat. Apo A-I and R2* increased
in parallel showing an internal consistency of the observations.
An obvious limitation of the present study is that only female
rats were investigated. As BPA is an estrogenic-acting compound
it cannot be taken for granted that different effects would not be
seen in males. Unfortunately, we  do not have reproducibility data
on the methods used in the paper. No detailed histopathological
examinations of the livers were performed.
The study was  performed during 10 weeks of exposure. A longer
exposure period might result in effects on the obesity measures
used.
5. Conclusions
In the present study we  found no evidence that BPA exposure
affects fat mass in fructose-fed juvenile Fischer 344 rats. We  also
suggest that the increase in liver fat inﬁltration and apo A-I may
result from combination effects of fructose and BPA exposure, and
eventually may  lead to more severe metabolic consequences. The
present ﬁndings would motivate future studies regarding these
more long term metabolic consequences. If so, the ﬁnding that fruc-
tose fed rats exposed to BPA induced fat inﬁltration in the liver
at dosages close to the current TDI might be of concern given the
widespread use of this compound in our environment and since a
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